Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Surfactant supplementation in the lung.

Antonio Anzueto1

  • 1Department of Medicine, Division of Pulmonary Medicine/Critical Care Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. anzueto@uthscsa.edu

Respiratory Care Clinics of North America
|December 17, 2002
PubMed
Summary

Pulmonary surfactant alterations contribute to Acute Respiratory Distress Syndrome (ARDS). While exogenous surfactant shows promise, clinical trials have not yet confirmed its benefit for ARDS patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moving to better COPD care-changes to and challenges for GOLD.

American journal of respiratory and critical care medicine·2026
Same author

How artificial intelligence could improve the diagnosis and management of COPD: a perspective from GOLD.

American journal of respiratory and critical care medicine·2026
Same author

Association of SARS-CoV-2 infection with incident diabetes among U.S. Veterans in a prospective longitudinal cohort.

PloS one·2026
Same author

The Future of New Inhaled Phosphodiesterase Inhibitors in Chronic Obstructive Pulmonary Disease.

Open respiratory archives·2026
Same author

Dupilumab in COPD: A Pooled Analysis of Emergency Department Visits, Hospital Admissions, and Systemic Corticosteroid Use.

American journal of respiratory and critical care medicine·2026
Same author

Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials).

Advances in therapy·2026

Area of Science:

  • Pulmonary medicine
  • Critical care medicine

Background:

  • Pulmonary surfactant alterations are key in Acute Respiratory Distress Syndrome (ARDS) pathogenesis.
  • Surfactant deficiency impacts ARDS progression, prognosis, and patient susceptibility.
  • Exogenous surfactant therapy is being investigated for potential benefits in ARDS.

Purpose of the Study:

  • To review the role of pulmonary surfactant in ARDS.
  • To evaluate the efficacy of exogenous surfactant preparations in ARDS patients.

Main Methods:

  • Review of existing studies on surfactant therapy in ARDS.
  • Analysis of outcomes from large randomized clinical trials.

Main Results:

  • Exogenous surfactant preparations have shown potential to improve lung function.
  • Large randomized clinical trials have not demonstrated significant benefits of surfactant therapy in ARDS.

Conclusions:

  • The role of surfactant therapy in ARDS remains uncertain.
  • Further research is needed to optimize delivery, understand pathophysiology, and develop improved synthetic surfactants for ARDS treatment.

Related Experiment Videos